Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-04-19
2011-04-19
Schnizer, Richard (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C514S04400A
Reexamination Certificate
active
07928216
ABSTRACT:
External Guide Sequence (EGS) are described that target proteins required for generation and modification of the immunoglobulin and T-cell repertoire that are useful for treatment or prevention of inflammatory or related diseases. Formulations suitable for administration of an EGS for treatment of inflammatory or related disease are described. The formulations may be administered via inhalation, injection, or orally. The formulations may be in the form of an ointment, lotion, cream, gel, drop, suppository, spray, liquid, powder, granule, solution, suspension, capsule, or tablet. Methods of treating inflammatory or related diseases by administering an effective amount of an EGS in a pharmaceutically acceptable carrier are also described. In preferred embodiments, the disease is asthma, allergic rhinitis, food allergies, atopic skin disease such as eczema, IL-4 and/or IL-13 dependent malignancies, IL-4 and/or IL-13 dependent autoimmune diseases, atopic diseases, the flu, and diseases caused by IL-4 dependent replication of viruses.
REFERENCES:
patent: 5624824 (1997-04-01), Yuan et al.
patent: 5728521 (1998-03-01), Yuan et al.
patent: 5869248 (1999-02-01), Yuan et al.
patent: 6057153 (2000-05-01), George et al.
patent: 6610478 (2003-08-01), Takle et al.
patent: 6822087 (2004-11-01), Renzi
patent: 2003/0211583 (2003-11-01), Stein
patent: 2004/0175384 (2004-09-01), Mohapatra et al.
patent: WO 93/01286 (1993-01-01), None
patent: WO 93/22434 (1993-11-01), None
patent: WO 95/24489 (1995-09-01), None
patent: WO96/21731 (1996-07-01), None
patent: WO 99/66037 (1999-12-01), None
patent: WO 02/46417 (2002-06-01), None
Kristoffersen et al. (1994) Arch. Virol. 138:85-93.
Ennaciri et al. (2007) J. Leukocyte Biology 81:625-631.
Agrawal et al., “Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus”,Proc. Natl. Acad. Sci. USA, 85: 7079-7083 (1988).
Anderson, et al., “Effect of cystic fibrosis on inhaled aerosol boluses”,Am. Rev. Respir. Dis., 140: 1317-1324 (1989).
Arava et al., “Specific gene expression in pancreatic beta-cells: cloning and characterization of differentially expressed genes”,Diabetes, 48(3):552-556 (1999).
Aronica, et al., “Susceptibility to allergic lung disease regulated by recall responses of dual-receptor memory T cells”,J. Allergy Clin. Immunol., 114(6):1441-1448 (2004).
Blackburn, et al., “Adenosine mediates IL-13-induced inflammation and remodeling in the lung and interacts in an IL-13-adenosine amplification pathway”,J. Clin. Invest., 112(3):332-344 (2003).
Borish, et al., “Efficacy of soluble IL-4 receptor for the treatment of adults with asthma”,J. Allergy Clin.Immunol., 107(6):963-70 (2001).
Brown, et al., “Serologic Evidence of Prenatal Influenza in the Etiology of Schizophrenia”,Arch. Gen. Psychiatry, 61(8):774-780 (2004).
Bueving, et al., “Influenza vaccination in children with asthma: randomized double-blind placebo-controlled trial”,Am. J. Respir. Crit. Care Med., 169(4):488-493 (2003).
Christy, et al., “Effectiveness of influenza vaccine for the prevention of asthma exacerbations”,Arch. Dis. Child, 89(8):734-735 (2004).
Chu and Paul, “Expressed genes in interleukin-4 treated B cells identified by cDNA representational difference analysis”,Mol Immunol, 35:487-502 (1998).
Cohn, et al., “Asthma: mechanisms of disease persistence and progression”,Annu. Rev. Immunol., 22:789-815 (2004).
Dahl, et al., “Viral-induced T helper type 1 responses enhance allergic disease by effects on lung dendritic cells”,Nat. Immunol., 5(3):337-343 (2004).
De Longueville, “What are the candidate groups for pharmacotherapeutic intervention to prevent asthma?”,Pediatr. Allergy Immunol., 11(Suppl. 13):41-44 (2000).
Dent, et al., “T helper type 2 inflammatory disease in the absence of interleukin 4 and transcription factor STAT6”,Proc Natl Acad Sci U S A, 95:13823-13828 (1998).
Desmet, et al., “Selective blockade of NF-kappa B activity in airway immune cells inhibits the effector phase of experimental asthma”,J. Immunol., 173(9):5766-5775 (2004).
Dreyfus, et al., “An RNA external guide sequence ribozyme targeting human interleukin-4 receptor alpha mRNA”,Int. Immunopharmacol., 4(8):1015-1027 (2004).
Elias, “The relationship between asthma anc COPD. Lessons from transgenic mice”,Chest, 126(2Suppl.):111S.-116S (2004).
Essner, et al., “Functional interleukin-4 receptor and interleukin-2 receptor common gamma chain in human gastric carcinoma: a possible mechanism for cytokine-based therapy”,J. Gastrointest. Surg., 5:81-90 (2001).
ETAC Study Group, “Allergic factors associated with the development of asthma and the influence of cetitizine in a double-blind, randomised, placebo-controlled trial: First results of ETAC(R)”,Pediatr. Allergy Immunol., 9(3):116-124 (1998).
Finotto, et al., Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression,J. Exp. Med., 193:1247-1260 (2001).
Frippiat, et al., “The recombination-activating gene 1 of Pleurodeles waltl (urodele amphibian) is transcribed in lymphoid tissues and in the central nervous system”,Immunogenetics, 52(3-4):264-275 (2001).
Galizzi, et al., “Molecular cloning of a cDNA encoding the human interleukin 4 receptor”,Int. Immunol., 2(7):669-675 (1990).
Ge, et al., “Inhibition of influenza virus production in virus-infected mice by RNA interference”,Proc. Natl. Acad. Sci. USA, 101(23):8676-8681 (2004).
Georas, et al., “Stat6 inhibits human interleukin-4 promoter activity in T cells”,Blood, 92:4529-4538 (1998).
Gessner and Rollinghoff, “Biologic functions and signaling of the interleukin-4 receptor complexes”,Immunobiology, 201(3-4):285-307 (2000).
Gopalan, et al., “RNase P: variations and uses”,J Biol Chem, 277:6759-62 (2002).
Gorman, “Does parental exposure to influenza raise the risk of schizophrenia?”,Time, 164(7):80 (2004).
Graber, et al., “The distribution of IL-13 receptor alpha1 expression on B cells, T cells and monocytes and its regulation by IL-13 and IL-4”,Eur. J. Immuno., 28:4286-4298 (1998).
Grossman and Paul, “Autoreactivity, dynamic tuning and selectivity”,Curr. Opin. Immunol., 13:687-698 (2001).
Grunewald, et al., Upon prolonged allergen exposure IL-4 and IL-4Ralpha knockout mice produce specific IgE leading to anaphylaxis,Int Arch Allergy Immunol, 125:322-8 (2001).
Grunig, “IL-13 and adenosine: partners in a molecular dance?”,J. Clin.Invest., 112(3):329-31 (2003).
Guerrier-Takada, et al., “Inactivation of gene expression using ribonuclease P and external guide sequences”,Methods Enzymol, 313:442-56 (2000).
Hackstein, et al., “A novel polymorphism in the 5′ promoter region of the human interleukin-4 receptor alpha-chain gene is associated with decreased soluble interleukin-4 receptor protein levels”,Immunogenetics, 53:264-269 (2001).
Hall, Interleukin-4 receptor alpha gene variants and allergic disease,Respir. Res., 1:6-8 (2000).
Hansen and Kaattari, “The recombination activation gene 1 (RAG1) of rainbow trout (Oncorhynchus mykiss): cloning, expression, and phylogenetic analysis”,Immunogenetics, 42(3):188-195 (1995).
Heasman, “Morpholino oligos: making sense of antisense?”,Dev. Biol., 243(2):209-214 (2002).
Heidenreich and Eckstein, “Hammerhead ribozyme-mediated cleavage of the long terminal repeat RNA of human immunodeficiency virus type 1”,J. Biol. Chem. 267:1904-1909 (1992).
Herrick, et al., “Th2 responses induced by epicutaneous or inhalational protein exposure are differentially dependent on IL-4”,J. Clin. Invest., 105:765-775 (2000).
Hershey, et al., “The association of atopy with a gain-of-function mutation in the a
Elrifi, Esq. Ivor R.
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
Schnizer Richard
Yale University
LandOfFree
Nuclease resistant external guide sequences for treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nuclease resistant external guide sequences for treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nuclease resistant external guide sequences for treating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2630320